Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2009

Cerenis Receives $3.2M to Support Development of HDL Products

Cerenis Receives $3.2M to Support Development of HDL Products

Cerenis receives $3.2 millino to develop CER-001

  • Cerenis Therapeutics has received a €2.5 million, or approximately $3.2 million, investment to finance its pipeline of HDL-related products for the treatment of cardiovascular and metabolic diseases.

    The financing will support continued development of the company's CER-001 program (recombinant HDL), which is currently in preclinical studies.

    The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies.

    In 2008, the company initiated preclinical studies to enable an IND application for this product candidate. "This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development," says Jean-Louis Dasseux, Ph.D., president and CEO of Cerenis. "We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market."ADNFCR-2184-ID-19019095-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »